Emmes' Kriszha S. shared her gratitude after speaking at #ASCEND2024: "I'm incredibly thankful for the opportunity to present a poster and presentation about the Angelman Syndrome Video Assessment (ASVA) and how the video assessment methodology can be adapted for Rett Syndrome. I'd like to thank the International Rett Syndrome Foundation for accepting my abstract and hosting such a wonderful event. I always enjoy the thoughtful discussion with families and showcasing the innovative work done by Emmes."
Visit https://hubs.la/Q02Dhy4v0 to learn more.
#EmmesEndpointSolutions#Emmes#CRO#ClinicalTrials#RareDisease
#als is a neurodegenerative disease that primarily affects neurons involved in the control of movement, called “motor neurons”, in the brain and spinal cord. An early event in the pathogenesis of ALS is a loss of synaptic connections between motor neurons and between these neurons and other types of neurons. Spinogenix, Inc. is developing drugs (SPGs) that regenerate synaptic connections, thus having the potential to reverse this early step in disease progression.
Spinogenix, Inc. tested its lead compound, SPG302, which is currently in a Phase 1 clinical trial, in a mouse model of #als that is characterized by rapid progression of motor symptoms. In the video, two mice genetically engineered to develop ALS-like pathology and motor symptoms are shown. The mouse with a short tail served as a control, receiving a daily treatment with a placebo, while the mouse with the long tail was treated daily with SPG302, each treatment starting on Day 14 of life after symptoms had already begun. By day 22, the time this video was taken, the control mouse showed severe motor symptoms, including slow movement, splayed hind legs, tremor, and a hunched back posture. At this same time, the SPG302-treated mouse was showing motor behavior resembling that of a normal mouse, without gross changes in locomotion or posture.
#nevertoolate#nevergiveup#alsawarenesshttps://lnkd.in/gSbiupBG
📢new paper alert!
How does hyperT affect cisplatin HIPEC in OvCa? 🔥
Check out our results in the first RCT evaluating the effect of the hyperthermia component here:
https://lnkd.in/dxYkDuCkWim Ceelen
The progress of science passes through the sharing of practices, especially in cases such as modulated total body/marrow irradiation in which a standard does not (yet) exist.
I am very happy to have participated in this collaborative work.
"We compiled a sampling of the treatment techniques of intensity-modulated total body irradiation, total marrow irradiation and total marrow and lymphoid irradiation utilized by several centers across North America and Europe. This manuscript does not serve as a consensus guideline, but rather is meant to serve as a convenient reference for centers that are considering starting an intensity-modulated program."
#MedPhys#AAPM#TMI#TMLI#AuToMI
got fusion?… Catamaran does!
We're excited to invite you to a compelling Lunch Workshop at the upcoming ISASS meeting on April 27th in Miami, Florida. Drs. Scott Kutz and Matthew Davies, MD, FAANS, renowned experts in the field, will lead a dynamic session titled "Mastering the SI Joint: A Comprehensive Approach to Diagnosis, Intervention and New Fusion Evidence."
Workshop Focus:
- Advanced SI Joint Diagnosis: Gain insights into Dr. Kutz and Dr. Davies' proven approach to diagnosing SI joint issues.
- Catamaran® System Innovation: Explore the groundbreaking features of the Catamaran system designed to achieve true arthrodesis/fusion of the SI joint.
- Real-World Evidence from Post-Market Study: Drs. Kutz and Davies will present and analyze promising early fusion rate data observed with Catamaran in our ongoing clinical study.
We encourage you to register for the workshop and join us for this informative session. To register, scan the QR code below or click here https://hubs.ly/Q02q-FQY0#ISASS24#sijointfusion#sijointdysfunction#catamaran#sijoint#TenonMedical#spine#transfixsacroiliacjoint#jibkit#fusion#arthodesis
This case report presents noninfarction pathologic Q-waves, which were abolished by 12 mg IV adenosin. Case highlights the fact that an accelerated junctional rhythm can lead to the appearance of pseudoinfarction Q waves. https://ja.ma/4a20YnJ
The multi-national RESOLVE-AF trial enrolled its first patient in the EU today as Dr. Max Liebregts and Dr. Lucas Boersma completed the first case at St. Antonius Hospital Nieuwegein, The Netherlands. Boersma, the European PI for the international trial said, “I’m excited to participate in this study to evaluate Cortex’s EGF mapping as a promising approach to identify extra-pulmonary vein EGF sources and their phenotypes."
RESOLVE-AF is a prospective, international, multi-center trial to evaluate the use of the OptiMap™ System and OptiMap™ Catheter to identify extra-pulmonary vein EGF sources and their phenotypes.
#EPeeps, #AFablation
On March 31st, for World Theranostics Day, we celebrate how Theranostics is connecting healthcare.
Theranostics isn't just about treating diseases; it's about treating individuals. By combining diagnostic and therapeutic tools, it enables personalized medicine, and helps improve accuracy and increase efficiency..
Our commitment to innovation extends beyond imaging capabilities.
Through initiatives like the Solid Target Platform for our PETtrace cyclotron and the development of StarGuide , innovative digital SPECT/CT powered by CZT, and Omni Legend , digital PET/CT powered by Precision DL software.
We’re helping revolutionizing the way clinicians diagnose and treat cancer, improving access to cutting-edge technology and personalized solutions.
Let's recognize the impact of #Theranostics on healthcare and commit to advancing precision care for all.
https://lnkd.in/ekW9-8TU#GEHealthCare#FutureofHealthcare#WorldTheranosticsDay#PrecisionHealthcare
With Theranostics, physicians specifically target what they see. The goal is to target the tumor selectively and spare the normal organs. For that, they need post treatment SPECT/CT with the highest quality imaging to review. StarGuide our 3D digital SPECT/CT supports nuclear medicine departments around the globe treating Theranostics patients.
#worldTheranosticsday
Executive Director- Global GM , Molecular Imaging at GE HealthCare
On March 31st, for World Theranostics Day, we celebrate how Theranostics is connecting healthcare.
Theranostics isn't just about treating diseases; it's about treating individuals. By combining diagnostic and therapeutic tools, it enables personalized medicine, and helps improve accuracy and increase efficiency..
Our commitment to innovation extends beyond imaging capabilities.
Through initiatives like the Solid Target Platform for our PETtrace cyclotron and the development of StarGuide , innovative digital SPECT/CT powered by CZT, and Omni Legend , digital PET/CT powered by Precision DL software.
We’re helping revolutionizing the way clinicians diagnose and treat cancer, improving access to cutting-edge technology and personalized solutions.
Let's recognize the impact of #Theranostics on healthcare and commit to advancing precision care for all.
https://lnkd.in/ekW9-8TU#GEHealthCare#FutureofHealthcare#WorldTheranosticsDay#PrecisionHealthcare
CEO at Aparito - wholly owned subsidiary of Eli Lilly and Company
3wGreat to see data from our Atom5 video capture software platform developing further